摘要
目的探讨小剂量氯沙坦抗肝纤维化和降低肝静脉压力梯度(HVPG)的作用。方法采用复合因素法制作大鼠肝硬化门静脉高压症(PHT)模型,雄性Wistar大鼠随机分为3组:正常对照组7只、模型对照组6只和治疗组10只。治疗组给予氯沙坦2.5mg·kg-1.d-1。结果15d治疗结束后,与模型对照组比较,氯沙坦能够显著降低HVPG[(12.5±1.4)mmHg对(10.1±1.1)mmHg],其中肝静脉楔入压下降为著,且对平均动脉压无明显影响。氯沙坦可以减轻肝纤维化程度,降低血清透明质酸和丙氨酸转氨酶水平。结论小剂量氯沙坦能够安全有效地降低HVPG,减轻肝纤维化而用于肝硬化PHT的治疗。
Objective To investigate the effect of low dose of losartan on rats with portal hypertension （PHT）. Methods PHT models were induced by compound factors. A total of 32 rats were randomly divided into 3 groups： control group （ n = 7） ; model group （ n = 6） and treatment group （ n = 10）. Treatment group was given losartan （2.5 mg·kg^-1·d 115 d）. Results After treatment, compared with model group, hepatic venous pressure gradient （HVPG） was significantly decreased. [ From （12.5±1.4） mm Hg to （10.1±1.1 ） mm Hg], and wedge hepatic venous pressure （WHVP） was markedly decreased, and low dose of losartan has no impact on mean arterial preasure （MAP）. Besides, losartan can significantly attenuate the degree of hepatic fibrosis and lower the levels of serum HA and ALT. Conclusion Low dose of kxsartan can decrease HVPG effectively and safely, and attenuate the degree of hepatic fibrcsis. So it can be used to treat PHT.
